Findings of a review of data from three clinical trials challenge current best practice for use of the drug for primary prevention of heart disease or stroke -- otherwise known as atherosclerotic cardiovascular disease. The analysis of data from three international clinical trials points to a need for further evidence on best practice among adults already taking aspirin for cardiovascular disease prevention.
